{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:37:37Z","timestamp":1782992257491,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jiph.2023.04.015","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:17:26Z","timestamp":1682011046000},"page":"955-963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin \u2013 A real-world data and retrospective cost analysis"],"prefix":"10.1016","volume":"16","author":[{"given":"Christoph T.","family":"Baltin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rongisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wingen-Heimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Eisenmenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Fabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"von Stebut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jiph.2023.04.015_bib1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jemermed.2014.12.001","article-title":"Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital","volume":"48","author":"Pollack","year":"2015","journal-title":"J Emerg Med"},{"issue":"6","key":"10.1016\/j.jiph.2023.04.015_bib2","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3904\/kjim.2018.374","article-title":"The clinical and economic burden of community-onset complicated skin and skin structure infections in Korea","volume":"35","author":"Cho","year":"2020","journal-title":"Korean J Intern Med"},{"issue":"Suppl 3","key":"10.1016\/j.jiph.2023.04.015_bib3","article-title":"Current epidemiology, etiology, and burden of acute skin infections in the United States","volume":"68","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jiph.2023.04.015_bib4","first-page":"270","article-title":"Early discharge of infectious disease patients: an opportunity or extra cost for the Italian Healthcare System?","volume":"21","author":"Palmieri","year":"2013","journal-title":"Infez Med"},{"issue":"6","key":"10.1016\/j.jiph.2023.04.015_bib5","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.amjsurg.2009.08.045","article-title":"Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus","volume":"199","author":"Itani","year":"2010","journal-title":"Am J Surg"},{"issue":"12","key":"10.1016\/j.jiph.2023.04.015_bib6","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3111\/13696998.2015.1078339","article-title":"Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting","volume":"18","author":"Ektare","year":"2015","journal-title":"J Med Econ"},{"issue":"5","key":"10.1016\/j.jiph.2023.04.015_bib7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/21548331.2018.1506673","article-title":"Economic burden of hospital admissions for patients with acute bacterial skin and skin structure infections in the United States","volume":"46","author":"Keyloun","year":"2018","journal-title":"Hosp Pr (1995)"},{"issue":"3","key":"10.1016\/j.jiph.2023.04.015_bib8","first-page":"203","article-title":"Feasibility of outpatient self-administration of parenteral antibiotics","volume":"128","author":"Antoniskis","year":"1978","journal-title":"West J Med"},{"issue":"7","key":"10.1016\/j.jiph.2023.04.015_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ejim.2013.03.014","article-title":"Outpatient parenteral antibiotic therapy: principles and practice","volume":"24","author":"Seaton","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"2","key":"10.1016\/j.jiph.2023.04.015_bib10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/jac\/dkm210","article-title":"Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years","volume":"60","author":"Matthews","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.jiph.2023.04.015_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy143","article-title":"Health-related quality of life in outpatient parenteral antimicrobial therapy","volume":"5","author":"Keller","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.jiph.2023.04.015_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/acem.12287","article-title":"Demographic and treatment patterns for infections in ambulatory settings in the United States, 2006-2010","volume":"21","author":"May","year":"2014","journal-title":"Acad Emerg Med"},{"issue":"2","key":"10.1016\/j.jiph.2023.04.015_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/QCO.0000000000000430","article-title":"The role of dalbavancin in skin and soft tissue infections","volume":"31","author":"Bassetti","year":"2018","journal-title":"Curr Opin Infect Dis"},{"issue":"6","key":"10.1016\/j.jiph.2023.04.015_bib14","first-page":"501","article-title":"Frequent bacterial skin and soft tissue infections: diagnostic signs and treatment","volume":"13","author":"Sunderk\u00f6tter","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"10.1016\/j.jiph.2023.04.015_bib15","first-page":"345","article-title":"S2k-Leitlinie Haut- und WeichgewebeinfektionenAuszug aus \"Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2018\"","volume":"17","author":"Sunderk\u00f6tter","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jiph.2023.04.015_bib16","doi-asserted-by":"crossref","unstructured":"Plewig G., French L., Ruzicka T.,Kaufmann R., Hertl M., eds. Braun-Falco\u00b4s Dermatology. Springer Berlin Heidelberg; 2020. https:\/\/doi.org.10.1007\/978\u20133-662\u201358713-3.","DOI":"10.1007\/978-3-662-58713-3"},{"issue":"23","key":"10.1016\/j.jiph.2023.04.015_bib17","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"New Engl J Med"},{"issue":"13","key":"10.1016\/j.jiph.2023.04.015_bib18","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1517\/14656566.2015.1075508","article-title":"Dalbavancin for the treatment of acute bacterial skin and skin structure infections","volume":"16","author":"Ramdeen","year":"2015","journal-title":"Expert Opin Pharm"},{"issue":"10","key":"10.1016\/j.jiph.2023.04.015_bib19","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2023.04.015_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jgar.2019.02.007","article-title":"Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections","volume":"17","author":"Rappo","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"issue":"12","key":"10.1016\/j.jiph.2023.04.015_bib21","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14787210.2020.1798227","article-title":"Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)","volume":"18","author":"Bai","year":"2020","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"1","key":"10.1016\/j.jiph.2023.04.015_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40265-016-0666-0","article-title":"Single-dose dalbavancin: a review in acute bacterial skin and skin structure infections","volume":"77","author":"Garnock-Jones","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jiph.2023.04.015_bib23","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"issue":"4","key":"10.1016\/j.jiph.2023.04.015_bib24","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/0735-1097(93)90415-W","article-title":"Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery","volume":"22","author":"Cohen","year":"1993","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jiph.2023.04.015_bib25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40744-018-0124-4","article-title":"Healthcare utilization and direct costs in patients with ankylosing spondylitis using a large US administrative claims database","volume":"5","author":"Walsh","year":"2018","journal-title":"Rheuma Ther"},{"issue":"Pt A","key":"10.1016\/j.jiph.2023.04.015_bib26","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jad.2021.11.004","article-title":"Real-world evidence from a European cohort study of patients with treatment resistant depression: healthcare resource utilization","volume":"298","author":"Heerlein","year":"2022","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jiph.2023.04.015_bib27","article-title":"Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia Gravis in the United States","volume":"12","author":"Phillips","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.jiph.2023.04.015_bib28","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"376","author":"Husereau","year":"2022","journal-title":"Bmj"},{"issue":"7","key":"10.1016\/j.jiph.2023.04.015_bib29","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamasurg.2021.0534","article-title":"ISPOR reporting guidelines for comparative effectiveness research","volume":"156","author":"Massarweh","year":"2021","journal-title":"JAMA Surg"},{"issue":"4","key":"10.1016\/j.jiph.2023.04.015_bib30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1524-4733.2007.00301.x","article-title":"German recommendations on health economic evaluation: third and updated version of the Hanover Consensus","volume":"11","author":"Graf von der Schulenburg","year":"2008","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jiph.2023.04.015_bib31","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2023.04.015_bib32","unstructured":"BfArM 2020 (Federal Institute for Drugs and Medical Devices). https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Kodiersysteme\/klassifikationen\/icd-10-gm\/vorgaenger-bis-2020\/icd10gm2020_zip.html?nn=841246&cms_dlConfirm=true&cms_calledFromDoc=841246 (Accessed 03 Jan 2023)."},{"issue":"4","key":"10.1016\/j.jiph.2023.04.015_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14656566.2018.1442439","article-title":"A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections","volume":"19","author":"Turco","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.jiph.2023.04.015_bib35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijantimicag.2014.04.007","article-title":"Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria","volume":"44","author":"Eckmann","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2023.04.015_bib36","first-page":"Doc03","article-title":"Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG data","volume":"7","author":"Wilke","year":"2019","journal-title":"GMS Infect Dis"},{"key":"10.1016\/j.jiph.2023.04.015_bib37","unstructured":"Falconer S. Reduced hospital stays for skin infections treated with dalbavancin. In: 28th European Congress of Clinical Microbiology and Infectious Diseases ECCMID; 2018 Apr 21\u201324; Madrid, Spain. P0282."},{"issue":"5","key":"10.1016\/j.jiph.2023.04.015_bib38","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40261-021-01028-3","article-title":"Dalbavancin efficacy and impact on hospital length-of-stay and treatment costs in different gram-positive bacterial infections","volume":"41","author":"Poliseno","year":"2021","journal-title":"Clin Drug Invest"},{"issue":"1","key":"10.1016\/j.jiph.2023.04.015_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40121-019-00275-4","article-title":"Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: The ENHANCE Trial","volume":"9","author":"McCarthy","year":"2020","journal-title":"Infect Dis Ther"},{"issue":"7","key":"10.1016\/j.jiph.2023.04.015_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1732","article-title":"Cost-consequence analysis of single-dose dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections in a multisite healthcare system","volume":"73","author":"Gonzalez","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2023.04.015_bib41","unstructured":"Gelbe Liste 2022 (German Drug Dictionary Pharmindex Database). https:\/\/www.gelbe-liste.de. Accessed 12 January 2022."}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034123001363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034123001363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:16:36Z","timestamp":1761750996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034123001363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1876034123001363"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2023.04.015","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin \u2013 A real-world data and retrospective cost analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2023.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}